Compare CGNX & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CGNX | NUVL |
|---|---|---|
| Founded | 1981 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.9B | 8.3B |
| IPO Year | 1994 | 2021 |
| Metric | CGNX | NUVL |
|---|---|---|
| Price | $53.97 | $101.65 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 16 |
| Target Price | $57.91 | ★ $134.75 |
| AVG Volume (30 Days) | ★ 1.5M | 600.6K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.62% | N/A |
| EPS Growth | ★ 9.68 | N/A |
| EPS | ★ 0.68 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.52 | N/A |
| Revenue Next Year | $8.63 | $1,239.49 |
| P/E Ratio | $80.72 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $26.14 | $63.56 |
| 52 Week High | $59.88 | $113.02 |
| Indicator | CGNX | NUVL |
|---|---|---|
| Relative Strength Index (RSI) | 54.83 | 44.73 |
| Support Level | $40.76 | $97.94 |
| Resistance Level | $59.11 | $107.08 |
| Average True Range (ATR) | 1.74 | 3.51 |
| MACD | -0.07 | -0.36 |
| Stochastic Oscillator | 28.62 | 19.14 |
Cognex Corp provides machine vision products that help automate manufacturing processes. The firm's products include vision software, vision systems, vision sensors, and ID products. Vision software combines vision tools with a customer's cameras and peripheral equipment and can help with several vision tasks, including part location, identification, measurement, and robotic guidance. Vision systems combine a camera, processor, and vision software into a single package. Vision sensors deliver simple, low-cost solutions for common vision applications, such as checking the size of parts. Geographically, it operates in United states, Europe, Greater China and others. Cognex generates the maximum proportion of its sales in the United States and Europe.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.